Altimmune (ALT) Non Operating Investment Income (2017 - 2018)

Altimmune's (ALT) quarterly Non Operating Investment Income came in at $806224.0 in Q3 2018, up 258.61% year-on-year from $224821.1 in Q3 2017, and up 149.29% on a QoQ basis from -$1.6 million in Q2 2018.

Altimmune (ALT) Non Operating Investment Income (2017 - 2018) Analysis & Trends

Altimmune (ALT) has 2 years of Non Operating Investment Income data on file, last reported at $806224.0 in Q3 2018.

  • On a quarterly basis, Non Operating Investment Income rose 258.61% year-over-year to $806224.0 in Q3 2018; TTM through Sep 2018 was $1.3 million, a N/A change from a year earlier, with the FY2017 full-year figure at $97763.0, changed N/A from the prior year.
  • Non Operating Investment Income for Q3 2018 stood at $806224.0, up from -$1.6 million in the prior quarter.
  • Over the last five years, Non Operating Investment Income for ALT reached as high as $1.5 million in Q1 2018 and fell as low as -$1.6 million in Q2 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Oculis Holding AG 67,222.41 Bn 67,222.13 Bn - -
2 Nanobiotix 1,909.44 Bn 1,909.38 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.12 Bn 466.33 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.84 Bn 114.59 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.89 Bn 61.14 Bn 3.31 Bn -
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.64 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.34 Bn 34.34 Bn 959.66 Mn -
10 Altimmune 366.54 Mn 366.54 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2018 806,224.00
Sep 30, 2018 806,224.00
Jun 30, 2018 -1.64 Mn
Jun 30, 2018 -1.64 Mn
Mar 31, 2018 1.55 Mn
Mar 31, 2018 1.55 Mn
Dec 31, 2017 606,079.00
Dec 31, 2017 606,079.00
Sep 30, 2017 -508,316.00
Sep 30, 2017 -508,316.00